Anti-obesity Rx drugs market set to exceed $1,000 million by 2026
The global anti-obesity prescription drugs market is likely to rise at a 4.80% compound annual growth rate (CAGR) over the forecast duration from 2017 to 2026. The market is projected to be worth $1,000 million by 2026-end, according to a new report from Transparency Market Research.
Geography-wise, North America is projected to emerge as a leading region in the global anti-obesity drugs market during the forecast period. The awareness of obesity among the population and the hazards associated with the health situation have resulted in the anti-obesity prescription drugs market depicting flourished growth in the region over the years.
Changing lifestyles to propel anti-obesity drugs market
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze